Compare EVCM & PRCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EVCM | PRCT |
|---|---|---|
| Founded | 2006 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Medical Specialities |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 1.8B |
| IPO Year | 2021 | 2021 |
| Metric | EVCM | PRCT |
|---|---|---|
| Price | $10.96 | $28.98 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 8 | 9 |
| Target Price | $11.50 | ★ $51.13 |
| AVG Volume (30 Days) | 133.1K | ★ 1.1M |
| Earning Date | 03-12-2026 | 02-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $718,038,000.00 | $299,907,000.00 |
| Revenue This Year | N/A | $48.30 |
| Revenue Next Year | $5.60 | $29.44 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 22.13 | ★ 50.07 |
| 52 Week Low | $7.66 | $27.80 |
| 52 Week High | $14.41 | $75.29 |
| Indicator | EVCM | PRCT |
|---|---|---|
| Relative Strength Index (RSI) | 38.63 | 40.41 |
| Support Level | $10.40 | $28.76 |
| Resistance Level | $12.40 | $31.35 |
| Average True Range (ATR) | 0.65 | 1.46 |
| MACD | -0.20 | -0.09 |
| Stochastic Oscillator | 22.90 | 30.29 |
EverCommerce Inc provides tailored Software-as-a-Service solutions for service-based small- and medium-sized businesses (SMBs) in-home services, health services, and fitness & wellness. With a platform serving approximately 708,000 customers across three core verticals, including numerous micro-verticals, their solutions address diverse needs within these sectors. Revenue is mostly generated from the United States. Operating in a single segment, their vertically-tailored SaaS offerings cater to SMBs' specialized demands, enabling them to automate processes, generate business, and enhance customer loyalty. The majority of customers contribute modest revenue, with a small percentage contributing higher amounts.
PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. It develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, which are image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. Geographically, the company generates a majority of its revenue from the United States and also has a presence in markets outside the U.S.